SHIM
TGTX icon

Stone House Investment Management’s TG Therapeutics TGTX Stock Holding History

Stone House Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.2K Sell
1,000
-3
-0.3% -$89 0.01% 223
2025
Q4 		$29.9K Hold
1,003
– – ﹤0.01% 213
2025
Q3 		$36.2K Buy
+1,003
New +$33K 0.01% 179

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Stone House Investment Management's TGTX Position: Q1 2026 in Review

Stone House Investment Management reduced its TG Therapeutics (TGTX) stake by 0.3% in Q1 2026, selling an estimated $89 and leaving 1,000 shares worth $33.2K. The position accounts for 0.01% of the portfolio, ranked #223.

Stone House Investment Management first reported a position in TGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $36.2K in Q3 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Stone House Investment Management held 1,000 shares of TG Therapeutics worth $33.2K as of Q1 2026.
  • Stone House Investment Management sold 3 TG Therapeutics shares in Q1 2026, an estimated $89.
  • TG Therapeutics made up 0.01% of Stone House Investment Management's portfolio in Q1 2026, its #223 holding.
  • Stone House Investment Management first reported a position in TG Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Stone House Investment Management's TG Therapeutics position peaked at $36.2K in Q3 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.